Andere Sprachen Virpax Pharmaceuticals, Inc.

Aktien

A404GA

US9282512063

VRPX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 25.06.2024			% 5 Tage	% 1. Jan.
0,5024 ^USD	+1,07 %		-11,88 %	-84,30 %

22.05.	VIRPAX PHARMACEUTICALS, INC. : Maxim ist weniger optimistisch	ZM
15.05.	Virpax bepreist öffentliches Angebot von Aktien und Optionsscheinen; Aktien stürzen ab	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Virpax Pharmaceuticals to Present at 2024 BIO International Convention	30.05.
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention	29.05.
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	15.05.
Top Premarket Decliners	15.05.
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15.05.
Virpax Announces Pricing of $2.25 Million Public Offering	15.05.
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments	13.05.
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Virpax Pharmaceuticals, Inc. Announces Resignation of Jeffrey Gudin as Chief Medical Officer and Executive Vice President	02.05.
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur	01.05.
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™	30.04.
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	30.04.
Virpax Pharmaceuticals Reports 2023 Year-End Results	26.03.
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	15.03.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price	28.02.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price	27.02.
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.	27.02.
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research	07.02.
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Virpax Pharmaceuticals, Inc.

Aktien

A404GA

US9282512063

VRPX

Andere Sprachen

Filter